Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 18/20 | 0.60 |
| ▸ | CDK2 | P24941 | 18/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 18/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230731 | 0.80 | CCNA2 (0.73) | CCNA2CDK2CCNA1 | |
| SCHEMBL6795093 | 0.76 | CCNA2 (0.71) | CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL6790434 | 0.75 | CCNA2 (0.70) | CCNA2CDK2CCNA1 | |
| SCHEMBL5229867 | 0.75 | CCNA2 (0.66) | CCNA2CDK2CCNA1 | |
| SCHEMBL5230996 | 0.75 | CCNA2 (1.00) | CCNA2CDK2CCNA1 | |
| SCHEMBL6792639 | 0.73 | CCNA2 (0.63) | CCNA2CDK2CCNA1 | |
| SCHEMBL5227785 | 0.73 | CCNA2 (0.85) | CCNA2CDK2CCNA1 | |
| SCHEMBL3603926 | 0.73 | LMNA (0.46) | ALDH1A1KMT2A | |
| SCHEMBL5230280 | 0.72 | CCNA2 (0.57) | CCNA2CDK2CCNA1MEN1ALDH1A1 | |
| SCHEMBL6791745 | 0.72 | CCNA2 (0.64) | CCNA2CDK2CCNA1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118102-B1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | disclosed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | disclosed |
| EP-2118102-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008065054-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | CDC7, CDK7, CDK17 | CCNA2 75/4885CDK2 9/4885CCNA1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.